The New Shape of Weight Loss: Inside the GLP-1 Revolution Reshaping How the World Eats
If you’ve been wondering why snack aisles look a little quieter and why your favourite soft drink brand suddenly launched a “protein-infused” version (no, that wasn’t in your imagination), the answer comes with three syllables and a hyphen: GLP-1.
These medications—Ozempic, Wegovy, Mounjaro, Zepbound, and their increasingly crowded extended family—aren’t just changing waistlines. According to new Rabobank research, they’re altering global food demand with all the subtlety of a polite bulldozer.
In its global report, Every Bite Counts: GLP-1s and the Future of Food (Rabobank RaboResearch), the bank declares that “weight loss medications mark a turning point for food consumption”, with a “ripple effect” now visible across entire economies.
Their message to the food industry? Buckle up. Dinner is changing.
Advertisement:
What Exactly Are GLP-1 Medications?
GLP-1s—short for glucagon-like peptide-1 receptor agonists—mimic a natural gut hormone that regulates appetite, slows digestion, and stabilises blood sugar. They were originally developed for diabetes, before doctors noticed a surprising side effect: people were losing large amounts of weight, and, more curiously, losing interest in food altogether.
As Rabobank puts it: “Users of these medicines eat both less and differently.”
This isn’t a fad. It’s biology getting a software update.
The Global Surge: Who’s Using These Drugs?
Rabobank’s data shows uptake accelerating in the US, UK, Europe—and yes, Australia is right behind them, adjusting its belt buckle in unison.
- In the United States, nearly 12% of adults have used a GLP-1 for weight loss, according to RAND.
- In the United Kingdom, between 4% and 7% of adults use these medications—a proportion now roughly equal to the percentage of vegetarians.
- In Australia, RaboResearch Australia general manager Stefan Vogel says “close to half a million people—approximately two per cent of the adult population—currently use GLP-1-style medications.”
His team cites public-health research showing Australian GLP-1 sales have increased tenfold since May 2020, reaching 496,875 units in April 2025.
Source: The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025 https://www.medrxiv.org/content/10.1101/2025.10.30.25339120v1.full.pdf
And globally, adoption is set to climb even higher as:
- prices fall
- oral GLP-1 pills arrive
- insurance coverage expands
In other words, this revolution is still warming up.
Advertisement:
Why These Drugs Are So Effective
GLP-1s don’t rely on willpower; they recalibrate hunger itself.
People describe the disappearance of “food noise” — that constant mental chatter steering you toward snacks, leftovers, and the occasional midnight pantry raid. For many, it’s the first time eating feels optional rather than inevitable.
Rabobank says two mechanisms are driving the food-sector shockwave:
- Appetite suppression
“Appetite suppression reduces overall food intake and makes portion-controlled, nutrient-dense foods more sought after,” Vogel explains. - Altered taste perception
Cravings dull. Intensity matters less. Texture, aroma, and presentation matter more. As the report puts it, indulgence increasingly comes from multi-sensory experience rather than sugar overload.
The Consumer Shift: What People Are (and Aren’t) Eating
Rabobank’s findings paint a remarkable picture of changing kitchens and changing supermarket baskets.
Early estimates suggest GLP-1 usage has already reduced global food and beverage consumption by 1–2%, led by the US.
A large US study cited in the report found households with at least one GLP-1 user slashed their grocery spend by approximately 6% within six months.
What dropped?
- Calorie-dense snacks
- Bakery sweets
- Soft drinks
- Processed carbs
- Alcohol (yes, that too)
- Meat and eggs also “fell in line” with overall reduced grocery spend.
What increased?
- High-protein dairy
- Nutrition bars
- Fresh produce
- Fortified beverages
- Prebiotics and probiotics
- Electrolyte-enhanced drinks
- Foods that pack maximum nutrients into smaller portions
As Vogel notes: “The winners are producers of fresh produce and high-protein foods and food supplements.”
Snacks can also survive—if they evolve. “Less but better,” the report says, will become the guiding principle of future product development.
Advertisement:
The Food Industry’s Wake-Up Call
GLP-1s aren’t inventing new trends; they’re intensifying ones already reshaping global diets:
- the high-protein boom
- the gut-health obsession
- portion control
- the rejection of ultra-processed foods
- hydration and electrolyte-rich products
- nutrient density over empty calories
- mindful indulgence
Food companies must now adapt or watch their products gather dust on supermarket shelves.
As Rabobank bluntly states: “No food category is immune.”
The Social Impact: Households Changing Together
One unexpected twist: the household effect.
“Users of GLP-1s are changing their eating habits and often also those of the whole household,” Vogel says, especially in reducing high-sugar and high-fat items.
Even moderate alcohol drinkers report a sudden disinterest in wine and beer—a change that Rabobank says will hit sugar, wine, and beer producers hardest.
Meanwhile, high-protein dairy finds itself experiencing a renaissance it hasn’t seen since bodybuilders discovered Greek yoghurt.
The Psychological Shift: Weight Loss Without the Food Fight
The quiet mind—where cravings used to buzz—is perhaps the most profound effect.
People who’ve spent decades dieting describe GLP-1 medications as life-changing, not because the kilos fall off, but because the shame and struggle fall away too.
Of course, psychology is never simple. Remove food as a coping mechanism and new emotional challenges emerge. But overall, the mental load of eating finally eases.
Criticism, Cost, and the Big Questions
Not everyone is cheering.
Concerns include:
- affordability
- long-term dependence
- unequal access
- medicalisation of body size
- pressure on healthcare budgets
- muscle loss (which can be countered with higher protein intake, as Rabobank notes)
Then there’s the classic: “Isn’t this just a shortcut?”
To which science replies: no. It’s treatment for a chronic disease affecting billions.
So, Is This the Future?
Almost certainly. And the food industry knows it.
GLP-1 medications are becoming a structural force—like veganism, paleo, Atkins, or low-carb were in their day—but on a scale those movements could only dream of.
As Rabobank puts it: “Not everyone will use GLP-1s, but the user base will grow large enough to shape mainstream demand.”
Food consumption won’t disappear, but it will evolve. The next decade will be defined by smarter calories, stronger proteins, better gut health, and fewer mindless snacks.
And if the world does become a little healthier—albeit by injection rather than intention—well, that’s one for the history books.
Related stories
Can civilisation survive without chocolate, wine and coffee?
Proof that weather modification exists
The Best of Australian Wine: Halliday Wine Companion
Ten best Brandy Cocktail recipes
French wine lovers love Montmartre Grape Harvest Festival
PR firms are spreading climate misinformation. Can we stop them?
Unmasking Greenwashing: ACCR Takes Santos to Federal Court
Meet the Frackers: Gas explorers in Australia
Advertisement:
